Pfizer Inc. has agreed to acquire Metsera Inc., a clinical-stage biopharmaceutical company accelerating medicines for obesity and cardiometabolic diseases, for a total enterprise value of approximately $4.9 billion. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in-class efficacy and safety profiles. “Obesity is a large and growing space with over 200 health conditions...